Seyed Ali Dehghan Manshadi, Shahin Merat, Minoo Mohraz, Mehrnaz Rasoolinejad, Shanaz Sali, Masoud Mardani, Payam Tabarsi, Mohammad-Hossein Somi, Roya Sedghi, Katayoun Tayeri, Mehri Nikbin, Jalal Karimi, Amir-Houshang Sharifi, Saeed Kalantari, Alireza Norouzi, Dorsa Merat, Zeinab Malekzadeh, Babak Mirminachi, Hossein Poustchi, Reza Malekzadeh
BACKGROUND: The current recommendation for treating hepatitis C virus (HCV) in HIV patients includes the combination of sofosbuvir (SOF) and daclatasvir (DCV). DCV should be used at different doses to compensate for interactions with antiretroviral therapy (ART). Up to three pills a day might be required which will significantly add to the pill burden of these patients. In this study, we have used a single-tablet approach to treating HCV-HIV coinfection. METHODS: Patients coinfected with HIV and HCV were prospectively enrolled from 10 centers throughout the country...
April 30, 2021: International Journal of Clinical Practice